Gastric Cancer Global Market Report 2025

Description

Gastric cancer is a malignant tumor that begins in the stomach lining, often starting in the mucosa, the innermost layer of the stomach. If left untreated, it can spread to deeper layers, surrounding tissues, or distant organs. Common risk factors for the disease include chronic infection with Helicobacter pylori, smoking, heavy alcohol consumption, an unhealthy diet, and genetic factors.

The main types of gastric cancers include adenocarcinoma, lymphoma, gastrointestinal stromal tumors, carcinoid tumors, and others. Adenocarcinoma, the most prevalent type, originates in the glandular cells of the stomach lining. Diagnosis is typically made through endoscopy, biopsy, imaging tests, exploratory surgery, and other methods. Treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, palliative care, and more. These treatments are distributed through various channels, including hospital pharmacies, specialty and retail pharmacies, among others.

The gastric cancer market research report is one of a series of new reports from The Business Research Company that provides gastric cancer market statistics, including gastric cancer industry global market size, regional shares, competitors with a gastric cancer market share, detailed gastric cancer market segments, market trends and opportunities, and any further data you may need to thrive in the gastric cancer industry. This gastric cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastric cancer market size has grown rapidly in recent years. It will grow from $3.17 billion in 2024 to $3.65 billion in 2025 at a compound annual growth rate (CAGR) of 15.4%. The growth during the historic period can be attributed to factors such as an increasing geriatric population, rising healthcare awareness, a growing number of genetic mutations, the adoption of unhealthy lifestyles, and heightened awareness about cancer.

The gastric cancer market size is expected to see rapid growth in the next few years. It will grow to $6.43 billion in 2029 at a compound annual growth rate (CAGR) of 15.2%. In the forecast period, growth is expected due to rising obesity rates, growing government initiatives, increased healthcare investments, a higher demand for oral drugs, and the expanding number of cancer treatment facilities. Key trends during this period include combination chemotherapy, product expansion, robotic-assisted surgery, targeted therapies, strategic collaborations, and the development of advanced diagnostic tools.

The growing rates of obesity are expected to drive the expansion of the gastric cancer market in the future. Obesity is a medical condition characterized by excessive body fat, often defined by a body mass index (BMI) of 30 or higher, which can lead to various health complications. The increase in obesity rates can be attributed to factors such as poor dietary habits, lack of exercise, sedentary lifestyles, environmental influences, and genetic factors. Excess body fat, especially visceral fat around the abdomen, is linked to an elevated risk of developing gastric cancer. Obesity causes chronic inflammation and metabolic imbalances, both of which are associated with cancer development, thereby contributing to a higher demand for gastric cancer treatments. For example, the World Health Organization reported in March 2024 that approximately 1 in 8 people globally were living with obesity in 2022. Around 2.5 billion adults aged 18 and older were considered overweight, with 890 million classified as obese. Among adults, 43% were overweight, and 16% were obese. Additionally, 37 million children under 5 were overweight, and more than 390 million children and adolescents aged 5-19 were overweight, including 160 million living with obesity. As a result, rising obesity rates are fueling the demand for gastric cancer treatments.

Leading companies in the gastric cancer market are focused on developing advanced solutions, such as companion diagnostic assays, to ensure personalized treatment. Companion diagnostic assays are tests that identify patients likely to benefit from specific treatments based on certain biomarkers. In October 2024, F. Hoffmann-La Roche Ltd., a pharmaceutical company based in Switzerland, received approval from the U.S. Food and Drug Administration (FDA) for the VENTANA CLDN18 (43-14A) RxDx Assay. This was the first immunohistochemistry (IHC) companion diagnostic for assessing CLDN18 protein expression in gastric and gastroesophageal junction (GEJ) adenocarcinoma. The assay identifies patients eligible for targeted treatment with VYLOY (zolbetuximab) by detecting CLDN18 protein variants, particularly CLDN18.2. This test utilizes the OptiView DAB IHC Detection Kit on the BenchMark ULTRA instrument, advancing personalized healthcare and expanding treatment options for gastric and GEJ adenocarcinoma patients.

In June 2022, Panbela Therapeutics Inc., a US-based biopharmaceutical company, acquired Cancer Prevention Pharmaceuticals Inc. for an undisclosed amount. This acquisition allows Panbela Therapeutics to diversify its pipeline and address multiple therapeutic areas. The deal adds four clinical-stage assets, including two late-stage registration assets, enhancing the combined entity's potential. This strategic move strengthens Panbela's position in high-potential therapeutic areas. Cancer Prevention Pharmaceuticals Inc. is a biotechnology company in the US that develops therapeutics for gastric cancer treatment.

Major players in the gastric cancer market are F. Hoffmann La Roche Ltd., Merck And Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Samsung Biologics Co. Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Hanmi Pharmaceuticals, Mylan N.V., Taiho Oncology Inc., Hikma Pharmaceuticals PLC, Taiho Pharmaceuticals Co. Ltd., and AROG Pharmaceuticals Inc.

North America was the largest region in the gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastric cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gastric cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastric cancer market consists of revenues earned by entities by providing services such as cancer screening and early detection, genetic testing, personalized treatment planning, and research and development services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastric cancer market also includes sales of chemotherapeutic drugs, radiation therapy equipment, nutritional support products, surgical tools, and instruments. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastric Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastric cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastric cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastric cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Adenocarcinoma; Lymphoma; Gastrointestinal Stromal Tumor; Carcinoid Tumor; Other Types
2) By Diagnosis: Endoscopy; Biopsy; Imaging Tests; Exploratory Surgery; Other Diagnosis
3) By Treatment: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Palliative Care; Other Treatments
4) By Distribution Channel: Hospital Pharmacies; Specialty And Retail Pharmacies; Other Distribution Channels
Subsegments:
1) By Adenocarcinoma: Intestinal Type Adenocarcinoma; Diffuse Type Adenocarcinoma; Mixed Type Adenocarcinoma
2) By Lymphoma: Primary Gastric Lymphoma; Secondary Gastric Lymphoma
3) By Gastrointestinal Stromal Tumor (GIST): Primary GIST; Metastatic GIST
4) By Carcinoid Tumor: Gastric Carcinoid Type 1; Gastric Carcinoid Type 2; Gastric Carcinoid Type 3
5) By Other Types: Small Cell Carcinoma; Squamous Cell Carcinoma; Mixed Tumors
Companies Mentioned: F. Hoffmann La Roche Ltd.; Merck And Co. Inc.; AbbVie Inc.; Sanofi S.A.; Bristol Myers Squibb Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r33727

1. Executive Summary

2. Gastric Cancer Market Characteristics

3. Gastric Cancer Market Trends And Strategies

4. Gastric Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Gastric Cancer Growth Analysis And Strategic Analysis Framework

5.1. Global Gastric Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Gastric Cancer Market Growth Rate Analysis
5.4. Global Gastric Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Gastric Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Gastric Cancer Total Addressable Market (TAM)

6. Gastric Cancer Market Segmentation

6.1. Global Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adenocarcinoma
Lymphoma
Gastrointestinal Stromal Tumor
Carcinoid Tumor
Other Types
6.2. Global Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Endoscopy
Biopsy
Imaging Tests
Exploratory Surgery
Other Diagnosis
6.3. Global Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Surgery
Radiation Therapy
Chemotherapy
Targeted Therapy
Palliative Care
Other Treatments
6.4. Global Gastric Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Specialty And Retail Pharmacies
Other Distribution Channels
6.5. Global Gastric Cancer Market, Sub-Segmentation Of Adenocarcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intestinal Type Adenocarcinoma
Diffuse Type Adenocarcinoma
Mixed Type Adenocarcinoma
6.6. Global Gastric Cancer Market, Sub-Segmentation Of Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Primary Gastric Lymphoma
Secondary Gastric Lymphoma
6.7. Global Gastric Cancer Market, Sub-Segmentation Of Gastrointestinal Stromal Tumor (GIST), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Primary GIST
Metastatic GIST
6.8. Global Gastric Cancer Market, Sub-Segmentation Of Carcinoid Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gastric Carcinoid Type 1
Gastric Carcinoid Type 2
Gastric Carcinoid Type 3
6.9. Global Gastric Cancer Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Small Cell Carcinoma
Squamous Cell Carcinoma
Mixed Tumors

7. Gastric Cancer Market Regional And Country Analysis

7.1. Global Gastric Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Gastric Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gastric Cancer Market

8.1. Asia-Pacific Gastric Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gastric Cancer Market

9.1. China Gastric Cancer Market Overview
9.2. China Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gastric Cancer Market

10.1. India Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gastric Cancer Market

11.1. Japan Gastric Cancer Market Overview
11.2. Japan Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gastric Cancer Market

12.1. Australia Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gastric Cancer Market

13.1. Indonesia Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gastric Cancer Market

14.1. South Korea Gastric Cancer Market Overview
14.2. South Korea Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gastric Cancer Market

15.1. Western Europe Gastric Cancer Market Overview
15.2. Western Europe Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gastric Cancer Market

16.1. UK Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gastric Cancer Market

17.1. Germany Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gastric Cancer Market

18.1. France Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gastric Cancer Market

19.1. Italy Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gastric Cancer Market

20.1. Spain Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gastric Cancer Market

21.1. Eastern Europe Gastric Cancer Market Overview
21.2. Eastern Europe Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gastric Cancer Market

22.1. Russia Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gastric Cancer Market

23.1. North America Gastric Cancer Market Overview
23.2. North America Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gastric Cancer Market

24.1. USA Gastric Cancer Market Overview
24.2. USA Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gastric Cancer Market

25.1. Canada Gastric Cancer Market Overview
25.2. Canada Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gastric Cancer Market

26.1. South America Gastric Cancer Market Overview
26.2. South America Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gastric Cancer Market

27.1. Brazil Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gastric Cancer Market

28.1. Middle East Gastric Cancer Market Overview
28.2. Middle East Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gastric Cancer Market

29.1. Africa Gastric Cancer Market Overview
29.2. Africa Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gastric Cancer Market Competitive Landscape And Company Profiles

30.1. Gastric Cancer Market Competitive Landscape
30.2. Gastric Cancer Market Company Profiles
- 30.2.1. F. Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Gastric Cancer Market Other Major And Innovative Companies

31.1. Abbott Laboratories
31.2. Novartis AG
31.3. GlaxoSmithKline Plc
31.4. Eli Lilly and Company
31.5. Amgen Inc.
31.6. Gilead Sciences Inc.
31.7. Teva Pharmaceutical Industries Ltd.
31.8. Boehringer Ingelheim
31.9. Astellas Pharma Inc.
31.10. Daiichi Sankyo Company Limited
31.11. Eisai Co. Ltd.
31.12. Ipsen Biopharmaceuticals Inc.
31.13. Ono Pharmaceutical Co. Ltd.
31.14. Samsung Biologics Co. Ltd.
31.15. Celltrion Healthcare Co. Ltd.

32. Global Gastric Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gastric Cancer Market

34. Recent Developments In The Gastric Cancer Market

35. Gastric Cancer Market High Potential Countries, Segments and Strategies

35.1 Gastric Cancer Market In 2029 - Countries Offering Most New Opportunities
35.2 Gastric Cancer Market In 2029 - Segments Offering Most New Opportunities
35.3 Gastric Cancer Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer